Hikma Cancels More Shares as $250m Buyback Passes 10 Million Mark
I'm LongbridgeAI, I can summarize articles.Hikma Pharmaceuticals repurchased 434,734 shares between July 6-10, 2026, as part of its $250 million buyback program. The company plans to cancel these shares, reducing the total issued shares to 211,711,706. Cumulative repurchases now exceed 10.17 million shares at a cost of £138.9 million. This capital return strategy aims to boost earnings per share and signals management confidence, despite current analyst ratings being mixed with a 'Sell' recommendation from analysts and a 'Neutral' AI assessment.
Hikma Pharmaceuticals ( (GB:HIK) ) has provided an update.
Hikma Pharmaceuticals has continued the second tranche of its $250 million share repurchase programme, buying back 434,734 ordinary shares on the London Stock Exchange between 6 and 10 July 2026 at volume‑weighted average prices ranging from about 1,554p to 1,658p. The company plans to cancel these shares, which will reduce the number of shares in issue and lift earnings per share, and following settlement it will have 211,711,706 ordinary shares in issue (excluding treasury shares) and the same number of voting rights, while it has now repurchased over 10.17 million shares in total at a cumulative cost of roughly £138.9 million.
The ongoing buyback underscores Hikma’s active capital‑return strategy and signals management’s confidence in the group’s valuation and cash‑generation capacity. For shareholders, the cancellation of repurchased stock is expected to be accretive over time, modestly enhancing ownership stakes and potentially supporting the share price as the programme progresses within the competitive generics and specialty pharma sector.
The most recent analyst rating on (GB:HIK) stock is a Sell
with a £13.50 price target.
To see the full list of analyst forecasts on Hikma Pharmaceuticals stock,
see the GB:HIK Stock Forecast page.
Spark’s Take on HIK Stock
According to Spark, TipRanks’ AI Analyst, HIK is a Neutral.
The score is held back primarily by deteriorating 2025 cash generation and weaker cash conversion, despite solid profitability and a reasonably sound balance sheet. Technically the stock is in a strong uptrend, but overbought signals raise near-term volatility risk. Valuation (very low P/E as provided) and a ~3.7% dividend, plus a constructive earnings call with a buyback and clear long-term growth investments, support the overall rating.
To see Spark’s full report on HIK stock,
click here.
More about Hikma Pharmaceuticals
Hikma Pharmaceuticals is a multinational generics and specialty pharmaceuticals company listed in London and on Nasdaq Dubai. It focuses on developing, manufacturing and marketing injectable, branded and non‑branded generic medicines, with a strong presence in the U.S., MENA and European markets.
Average Trading Volume: 852,165
Technical Sentiment Signal: Hold
Current Market Cap: £3.33B
See more data about HIK stock on TipRanks’ Stock Analysis page.